Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-Burden and Control Efforts: A Narrative Scoping Review. Cancer Control. 2019;26:1073274819863802.

Tran HTT, Nguyen S, Nguyen KK, Pham DX, Nguyen UH, Le AT, et al. Lung Cancer in Vietnam. J Thorac Oncol. 2021;16:1443-1448.

Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17:362-387.

Ahmad AS, Mayya AM. A new tool to predict lung cancer based on risk factors. Heliyon. 2020;6:e03402.

Sim JA, Kim YA, Kim JH, Lee JM, Kim MS, Shim YM, et al. The major effects of health-related quality of life on 5 - year survival prediction among lung cancer survivors: applications of machine learning. Sci Rep. 2020;10:10693.

Greillier L, Gauvrit M, Paillaud E, Girard N, Montegut C, Boulahssass R, et al. Targeted Therapy for Older Patients with Non - Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French - Language Society of Pulmonology (SPLF)/French - Language Oncology Group (GOLF). Cancers (Basel). 2022;14.

Liu SY, Liu SM, Zhong WZ, Wu YL. Targeted Therapy in Early Stage Non - small Cell Lung Cancer. Curr Treat Options Oncol. 2022.

Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non - small cell lung cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188645.

Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, et al. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non - small Cell Lung Cancer: Targeting the Tumor Microenvironment. Int J Biol Sci. 2022;18:3845-3858.

Hong CS, Sun EG, Choi JN, Kim DH, Kim JH, Ryu KH, et al. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Cancer Sci. 2020;111:3268-3278.

Shanmugapriya K, Kim H, Kang HW. Epidermal growth factor receptor conjugated fucoidan/alginates loaded hydrogel for activating EGFR/AKT signaling pathways in colon cancer cells during targeted photodynamic therapy. Int J Biol Macromol. 2020.

Abu - Yousif AO, Moor AC, Zheng X, Savellano MD, Yu W, Selbo PK, et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett. 2012;321:120-7.

Heuckmann JM, Rauh D, Thomas RK. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol. 2012;30:3417-20.

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non - small - cell lung cancer considering first - line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-7.

Bironzo P, Reale ML, Sperone T, Tabbo F, Caglio A, Listi A, et al. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non - Small - Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. Cancers (Basel). 2021;13.

Jethwa M, Gangopadhyay A, Saha A. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches. J Biomol Struct Dyn. 2022:1-9.

Kaufman NEM, Dhingra S, Jois SD, Vicente M. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules. 2021;26.

Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, et al. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First - Line Therapy with a First - or Second - Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation - Positive Locally Advanced or Metastatic Non - Small Cell Lung Cancer: The ‘LUNGFUL’ Study. Cancers (Basel). 2021;13.

Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, et al. An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation - Positive Non - Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer (Auckl). 2021;12:93-102.

Liu Y, Zhang Y, Feng G, Niu Q, Xu S, Yan Y, et al. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non - small cell lung cancer: A network meta - analysis. Exp Ther Med. 2017;14:4017-4032.

Jiang H, Zhu M, Li Y, Li Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first - line EGFR - TKI treatment in patients with non - small cell lung cancer. Mol Clin Oncol. 2019;11:301-308.

Krawczyk P, Kowalski DM, Ramlau R, Kalinka- Warzocha E, Winiarczyk K, Stencel K, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non - small cell lung cancer in patients with common and rare EGFR gene mutations. Oncol Lett. 2017;13:4433-4444.

Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non - small cell lung cancer patients. Onco Targets Ther. 2014;7:513-24.

Liang H, Pan Z, Wang W, Guo C, Chen D, Zhang J, et al. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature - based pooled analysis. J Thorac Dis. 2018;10:2311-2320.

Reade CA , Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics. 2009;3:215-24.